Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio (Nasdaq: UPB) will present new Phase 2 VIBRANT data for verekitug at the American Thoracic Society (ATS) 2026 International Conference in Orlando on May 18, 2026.

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB) will present new Phase 2 VIBRANT data for verekitug at the American Thoracic Society (ATS) 2026 International Conference in Orlando on May 18, 2026. Two posters (P1397, P1398) by Joseph K. Han, MD, report clinical effects in CRSwNP with comorbid asthma and impacts on nasal and blood biomarkers.

The presentations cover verekitug as a thymic stromal lymphopoietin (TSLP) receptor antagonist and include biomarker and clinical outcome data from the VIBRANT trial.

Argus Apr 17 session

-1.09% close to close Open Argus

Details

News Market Reaction – UPB

In the Apr 17 session, UPB declined 1.09%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights upcoming Phase 2 VIBRANT trial presentations of verekitug in CRSwNP and...

Analysis

This announcement highlights upcoming Phase 2 VIBRANT trial presentations of verekitug in CRSwNP and comorbid asthma at ATS 2026, focusing on clinical effects and biomarker changes. It builds on prior positive readouts across VIBRANT and VALIANT noted in recent filings. Investors following the story may watch how these data integrate with plans for Phase 3 in severe asthma and CRSwNP, and how the company manages its cash position of $341.5 million alongside ongoing development across multiple respiratory indications.

Key Figures

Trial phase: Phase 2 Conference date: May 18, 2026 Session time: 11:30 AM – 1:15 PM ET +2 more

Trial phase

Phase 2

VIBRANT trial of verekitug in CRSwNP

Conference date

May 18, 2026

ATS 2026 International Conference poster presentations

Session time

11:30 AM – 1:15 PM ET

Both verekitug VIBRANT posters at ATS 2026

Poster board number

P1397

Verekitug CRSwNP with comorbid asthma presentation

Poster board number

P1398

Verekitug CRSwNP biomarker effects presentation

Previous Clinical trial Reports

4 past events · Latest: Feb 26

Same Type 4 events

1. Feb 26

   VIBRANT analyses

   24h Move

   +2.1%

   Additional Phase 2 VIBRANT CRSwNP analyses in late-breaking AAAAI poster.

2. Feb 11

   VALIANT top-line data

   24h Move

   -47.2%

   Positive Phase 2 VALIANT severe asthma results with significant AAER reductions.

3. Sep 02

   VIBRANT top-line data

   24h Move

   +18.3%

   Phase 2 VIBRANT CRSwNP trial met primary and key secondary endpoints.

4. Jul 08

   VENTURE trial start

   24h Move

   -0.7%

   First patient dosed in Phase 2 COPD trial expanding verekitug indications.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

thymic stromal lymphopoietin, tslp, receptor antagonist, chronic rhinosinusitis with nasal polyps, +1 more

5 terms

thymic stromal lymphopoietin medical

"the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently"

Thymic stromal lymphopoietin (TSLP) is a small signaling protein the body uses like an alarm bell to alert and steer immune cells, especially in barrier tissues such as the lungs and skin. It matters to investors because drugs that block or measure TSLP can reduce allergic inflammation and other immune-driven diseases; successful therapies or tests can drive regulatory approvals, market adoption and company value much like a new product that solves a widespread problem.

tslp medical

"the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently"

TSLP (thymic stromal lymphopoietin) is an immune-system signaling protein that acts like an alarm, triggering inflammation in conditions such as asthma and allergic disease. Investors watch TSLP because drugs that block its action can reduce symptoms and prevent flares; successful clinical trials or approvals for TSLP-targeting therapies can materially change a biotech company's prospects, market value, and potential market size for respiratory and allergic treatments.

receptor antagonist medical

"Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, Administered in Participants"

A receptor antagonist is a drug or molecule that attaches to a specific site on a cell and prevents that site from being turned on by the body’s own chemicals; think of it as putting a cap on a lock so the key can’t open it. Investors care because these compounds can form the basis of new medicines whose ability to block harmful signals affects clinical results, regulatory approval, market size, and future revenue potential.

chronic rhinosinusitis with nasal polyps medical

"in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include"

A long‑term inflammatory condition of the nose and sinuses that produces swollen tissue and small growths called nasal polyps, which can block airflow and reduce smell. It matters to investors because the condition is chronic, often requires ongoing medication or repeated procedures, and creates predictable demand for diagnostics, drugs and devices—similar to a recurring subscription—affecting revenue prospects and market size in respiratory and allergy-related healthcare.

biomarkers medical

"comorbid asthma, as well as its impact on nasal and blood biomarkers."

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc.  (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers.

Presentation details:

• Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, Administered in Participants with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma in the VIBRANT Trial
  Presenting Author: Joseph K. Han, MD, Old Dominion University
  Poster Board Number: P1397
  Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier
  Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET

• Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, in Chronic Rhinosinusitis with Nasal Polyps: Effect on Type 2 Inflammatory Biomarkers in the VIBRANT Trial
  Presenting Author: Joseph K. Han, MD, Old Dominion University
  Poster Board Number: P1398
  Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier
  Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET

About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What VIBRANT trial data will Upstream Bio (UPB) present at ATS 2026 on May 18, 2026?

They will present clinical effect and biomarker data from the Phase 2 VIBRANT trial in CRSwNP. According to Upstream Bio, two posters (P1397, P1398) report verekitug effects in participants with comorbid asthma and changes in nasal and blood biomarkers.

Who is the presenting author for Upstream Bio's (UPB) verekitug posters at ATS 2026?

Joseph K. Han, MD, from Old Dominion University is listed as the presenting author. According to Upstream Bio, Dr. Han will present both poster boards P1397 and P1398 in session B32 on May 18, 2026.

When and where will Upstream Bio (UPB) present the verekitug posters at ATS 2026?

Presentations are scheduled Monday, May 18, 2026, from 11:30 AM to 1:15 PM ET in Orlando, FL. According to Upstream Bio, both posters appear in session B32, titled 'Rise of the Biologics: A New Hope for Breathing Easier.'

What topics do Upstream Bio's posters P1397 and P1398 cover at ATS 2026?

Poster P1397 covers clinical effects of verekitug in CRSwNP with comorbid asthma; P1398 covers effects on type 2 inflammatory biomarkers. According to Upstream Bio, both derive from Phase 2 VIBRANT trial data.

What is verekitug and its relevance in the VIBRANT trial presented by Upstream Bio (UPB)?

Verekitug is described as a TSLP receptor antagonist in clinical development for respiratory disease. According to Upstream Bio, VIBRANT is a Phase 2 trial evaluating verekitug in chronic rhinosinusitis with nasal polyps and related biomarkers.

How can investors or clinicians access the verekitug data presented by Upstream Bio (UPB) at ATS 2026?

The data will be available as poster presentations during the ATS session on May 18, 2026. According to Upstream Bio, posters P1397 and P1398 will present the VIBRANT trial clinical and biomarker findings in session B32.